

Gilead Sciences, Inc.
Medical Affairs
HCV SCALE program: Screening Access and Linkage to Care

Through Medical Affairs, Gilead supports the efforts of academic institutions, clinical investigators, and research networks to help inform the scientific community about the impact of hepatitis C on patients and the health care system. Specifically, Gilead intends to support investigators focused on addressing the challenges associated with HCV screening, access, and linkage to care for individuals infected with hepatitis C.

Through the Medical Affairs Investigator Sponsored Research process, Gilead will evaluate support of programs which address the following objectives:

- HCV screening, access, and linkage to care studies for high risk and high prevalence populations and geographies, including demonstration of clinical and economic value of such programs
- Development and performance of implementation science projects, including data collection or modeling, of screening, access, and linkage to care of HCV populations
- Studies should include the following elements:
 - Contain a defined population, such as a clinic, a health system, geographic location or other clearly defined group that can be followed for outcomes
 - Define specific data collection methods
 - Can be completed within 3 years
 - Collect appropriate metrics
 - Defined outcomes

Proposals must demonstrate the following:

- Clear scientific objectives based on a **scientific hypothesis**
- Potential **scalability and sustainability** of program to other practice settings
- Plan to publish and present results in scientific forums and to other organizations

Key Dates & Program Specifics:

- Letter of Interest (LOI) - 2 page concise overview of proposed project & draft budget
 - **31 March 2017**: LOI submission window opens
 - **05 May 2017** : LOI submission window closes

LOI applicants should use the downloadable **LOI Form** available at <http://www.gilead.com/research/investigator-sponsored>. LOI forms should be submitted to: scale@gilead.com.

- Full application submission

A review of the LOIs will result in invitations for selected LOI applicants to submit a full application. The timelines below pertain to full application submissions.

- **02 June 2017:** Notice of LOI outcome, either approved for full application submission or declined
- **14 July 2017:** Deadline for receipt of full application
- **04 August 2017:** Notice of full application outcome, provisional approval or declined

Full application submissions should be made by clicking on Apply Online at <http://www.gilead.com/research/investigator-sponsored>

The program provides awards for proposals completed in up to 3 years. Gilead plans to award a total of approximately \$9,000,000 in funds for these research proposals, dependent upon availability of funds and receipt of meritorious applications. Gilead anticipates that 8-12 awards will be granted. No individual study may exceed \$2,000,000. Awards shall be for research purposes only; **requests for HCV screening costs alone or for HCV study drug will not be considered.** Proposals should not require treatment with any particular HCV medication or drug regimen.

Questions about the announcement or application process should be submitted to your local Gilead Medical Scientist or scale@gilead.com. Gilead reserves the right to approve or disapprove any application. Applications are reviewed by an internal review committee. Award of a grant in any one cycle does not infer that a subsequent grant will be awarded without further application and approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.